Requests similar to 'Membership re Clinical Trials, Biologicals and Vaccines EAG'

Pfizer Covid 19 (BNT162b2) Vaccine
Response by Medicines and Healthcare Products Regulatory Agency to A. I. Clayton on .

Awaiting classification

Dear A I Clayton   Re: FOI 24/189   Please find attached the response and disclosure documents for your request FOI 24/189. Please accept our...
BNT162b2 all case mortality data from Pfizer clinical trials dossier, dates sent to scientific/medical advisers.
Response by Medicines and Healthcare Products Regulatory Agency to J Grove on .

Awaiting classification

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...
Pfizer BNT162b2 conditions of authorisation
Response by Medicines and Healthcare Products Regulatory Agency to Alex Hicks on .

Refused

Dear Alex Hicks,   Please find attached our response to your request for an Internal Review.   MHRA Customer Experience Centre Communications...
Contamination, exact ingredients and WFI GMP for Pfizer's product BNT162b2
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful

Internal Review of FOI 22/387   Dear Mr Jonathan Weissman   Thank you for your email.   Please find attached the reply to your Internal Rev...
Essential safety documents relating to BNT162b2
Response by Medicines and Healthcare Products Regulatory Agency to Matt Cooper on .

Information not held

Internal Review of FOI 22/517 Dear Matt Cooper, Thank you for your email. Please find attached the response to your Internal Review request. Kind R...
ALC-0159 purity and tetrahydrofuran contamination in Pfizer's BNT162b2
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Refused

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...
RNA integrity of experimental modRNA COVID-19 drugs (Pfizer and Moderna)
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Refused

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...
Covid 19 vaccine adverse reactions in people taking methotrexate
Response by Medicines and Healthcare Products Regulatory Agency to Graham Crawley on .

Information not held

Dear Mr Crawley, Please find attached the response to your FOI request. Kind regards,   FOI Team Vigilance and Risk Management of Medicines D...
Covid 19 vaccine adverse reactions in people on anti-coagulants
Response by Medicines and Healthcare Products Regulatory Agency to Graham Crawley on .

Information not held

Dear Mr Crawley, Please find attached the response to your FOI request. Kind regards,   FOI Team Vigilance and Risk Management of Medicines Division...
Covid 19 vaccine adverse reactions in people taking TNF inhibitors
Response by Medicines and Healthcare Products Regulatory Agency to Graham Crawley on .

Information not held

Dear Mr Crawley, Please find attached the response to your FOI request. Kind regards,   FOI Team Vigilance and Risk Management of Medicines D...
Biodistribution, half-life and known toxicity of SARS-CoV-2 spike protein produced cellularly after COVID vaccination
Response by Medicines and Healthcare Products Regulatory Agency to Dr Lee Proctor on .

Long overdue

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...
Emergency Authorisation of Covid Vaccines: Criteria for End of Emergency
Response by Medicines and Healthcare Products Regulatory Agency to Branwen Sloper on .

Refused

FOI 22/412   Dear B Sloper,   Thank you for your email.   The Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK...
Test data and results for each batch of BNT162b2 independently tested by the NIBSC under Regulation 174A
Response by Medicines and Healthcare Products Regulatory Agency to Dr Lee Proctor on .

Awaiting classification

Dear Dr Lee Proctor, Thank you for your email. Please find attached the response and documents for your request. Kind Regards MHRA Customer Experie...
Quality control of excipients in modRNA Pfizer and Moderna COVID-19 drugs
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Refused

FOI 22/476 Dear Jonathan Weissman, Thank you for your email. Details of the finished product specification for the finished product specifications f...
Lipid-related impurity issues for BNT162b2
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Awaiting classification

Dear Mr Weissman, We apologise for the delay in replying to this Internal Review, please find our response attached. Yours sincerely MHRA Customer E...
Mixing of mRNA vaccines at vaccination centres
Response by Medicines and Healthcare Products Regulatory Agency to Alex Hicks on .

Partially successful

Our reference: FOI 23/043   Dear Alex Hicks,   Thank you for your request under the Freedom of Information Act, we apologise for the long dela...
Questioning the authorisation of emergency use Covid-19 vaccines.
Response by Medicines and Healthcare Products Regulatory Agency to Ian Harper on .

Successful

Dear Ian Harper   Please find attached the response to your request FOI 24-005.   Yours sincerely   10 South Colonnade Canary Wharf London E...
Nucleotide base sequence for "Riltozinameran"
Response by Medicines and Healthcare Products Regulatory Agency to Matt Cooper on .

Successful

FOI 22/949   Dear Matt Cooper,   Thank you for your email.   Please find attached the response and additional document to your request.  ...
NaOH and HCl Excipients in Pfizer’s SmPC for Comirnaty
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful

FOI 23/325   Dear Mr Weissman,   Thank you for your request under the Freedom of Information Act, we apologise for the delay in response.  ...
PV Strategy Document, AESI spreadsheet, Pfizer case output files
Response by Medicines and Healthcare Products Regulatory Agency to D Jackson on .

Partially successful

Internal Review of FOI 22/912 Dear D Jackson, Thank you for your email. Please find attached the response and attached document to your Internal Rev...
Information on frameshifting
Response by Medicines and Healthcare Products Regulatory Agency to Clare Craig on .

Long overdue

 Dear Claire,   Please find our response to your FOI.   Kind regards,   FOI Team     Email 1 From: Sent: Wednesday, November 22, 2023...
Date of receipt of Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) received through 28 February 2021”
Response by Medicines and Healthcare Products Regulatory Agency to [Name Removed] on .

Awaiting classification

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...
Important protocol deviations within 7 days after Dose 2 in BNT162b2 clinical trial
Response by Medicines and Healthcare Products Regulatory Agency to Jonathan Weissman on .

Partially successful

FOI 23/211   Dear Mr Weissman,   Thank you for your information request dated 19 February 2022 where you asked for information related COVID-1...
Pfizer vaccine fertility and developmental study
Response by Medicines and Healthcare Products Regulatory Agency to J. Mwanzia on .

Successful

FOI 23/025   Dear J. Mwanzia,   Thank you for your request under FOIA, we sincerely apologise for the delay.   The study to which you refe...
How many deaths are too many with Pfizer BNT162B2 in order to halt deployment?
Response by Medicines and Healthcare Products Regulatory Agency to Graham Crawley on .

Refused

Thank you for your email.  This auto-response is to inform you that your email has been received and will be reviewed by our Customer Service Team. W...